PTEN and hepatocellular carcinoma: Sorafenib exposure resulted in upregulation of p‐Met, c‐Met, p‐Akt, and p‐ERK, and downregulation of PTEN, in both parental and sorafenib‐resistant HCC cells (Fig. 2D).